Saddle Brook, New Jersey Clinical Trials

A listing of Saddle Brook, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 74 clinical trials
Using Direct Brain Stimulation to Study Cognitive Electrophysiology

This project forms a multi-site research collaboration to carry out verbal and spatial memory experiments in patient volunteers to better understand the neural bases of human memory, employing direct electrical brain stimulation as a tool to study those dynamics and their relationship to memory performance.

brain stimulation
electrical stimulation
epilepsy
Columbia University
 (9.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +5 other locations
Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab

This is an open-label, multicenter study that includes a main study for all participants enrolled and an optional cerebrospinal fluid (CSF) sub-study. Self-identified African American (AA) and Hispanic or Latin American (HA) participants with a diagnosis of relapsing multiple sclerosis (RMS) will be enrolled. The treating neurologist must make an …

Hackensack University Medical Center
 (2.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +30 other locations
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

This is a global, Phase 1/2, multicenter, open-label study. The clinical study will include of Phase 1: Dose Escalation (non-randomized, dose finding study) and Phase 2: Dose Expansion (randomized efficacy exploration). For Phase 1, the purpose of this study is to assess the maximum tolerated dose (MTD), recommend phase 2 …

glioblastoma multiforme
renal function test
MRI
recurrent disease
measurable disease
Hackensack Meridian Health, 92 Second Street
 (2.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients

A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.

cardiac arrest
life support
hypothermia
resuscitation
induced hypothermia
NYP Columbia University Medical Center
 (8.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +12 other locations
Manhattan Vision Screening and Follow-Up Study

The investigators are conducting a 5-year prospective, cluster-randomized controlled trial, funded by the Centers for Disease Control (CDC), which provides vision screenings to underserved, vulnerable New York City residents living in affordable housing buildings in Harlem and Washington Heights.

vision screening
Columbia University
 (8.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

recurrent endometrial cancer
endometrial cancer
cancer therapy
paclitaxel
cancer
Research Site
 (3.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +94 other locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

stage iiia lung cancer ajcc v7
gemcitabine
stage ii lung cancer ajcc v7
stage iia lung squamous cell carcinoma ajcc v7
non-small cell carcinoma
Neurosurgeons of New Jersey-Ridgewood
 (5.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +358 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
antihemophilic factor
factor ix
hemophilia
fitusiran
Investigational Site Number 8400008
 (2.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …

hepatitis b surface antigen
hbv dna
dexamethasone
arginine hydrochloride
antibiotic therapy
Investigational Site Number 8400006
 (2.7 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +13 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
antihemophilic factor
factor ix
hemophilia
fitusiran
Investigational Site Number 8400008
 (2.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations